OMass is a biotechnology company harnessing native mass spectrometry and other biophysical technologies to drive drug discovery in high definition. The company’s suite of proprietary technologies delivers superior resolution to traditional pharmacology assays enabling a clearer, more detailed picture of how a putative ligand engages a protein target assessing binding and function in parallel. The additional information obtained in the OMass assays can reveal new biology even at well-studied receptors and the cell-free system is unbiased for different ligand chemistries unmasking chemical space of high therapeutic potential inaccessible to cell-based assays. The company is building a pipeline of small molecule therapeutics to bring life-changing benefits to patients suffering from immunology and genetic disorders. OMass is backed by Syncona Ltd Oxford Sciences Innovation and Oxford University.
For further information please visit the company’s website at: www.omass.com
Location: United Kingdom, England, Oxford
Total raised: $112.51M
Investors 6
| Date | Name | Website |
| 05.07.2023 | British Pa... | britishpat... |
| - | BioCity | biocity.co... |
| - | Oxford Uni... | innovation... |
| - | Syncona Pa... | synconaltd... |
| - | Oxford Sci... | oxfordscie... |
| 30.04.2022 | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.05.2023 | - | $12.51M | British Pa... |
| 06.05.2022 | Series B | $100M | - |
Mentions in press and media 13
| Date | Title | Description | Source |
| 08.04.2024 | OMass Therapeutics expands Scientific Advisory Board with th... | PRESS RELEASE OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Tei... | einpresswi... |
| 15.05.2023 | British Patient Capital Invests £10m in next generation drug... | 15 May 2023: British Patient Capital has made a £10 million investment into OMass Therapeutics, a pl... | britishpat... |
| 28.04.2022 | GV, Sanofi drive British biotech OMass to $100M series B, fu... | GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therap... | fiercebiot... |
| 28.04.2022 | OMass Therapeutics Raises $100 Million in Series B Financing... | PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline... | globenewsw... |
| 06.04.2022 | Publication in Nature by OMass Founder, Professor Dame Carol... | PRESS RELEASE Publication in Nature by OMass Founder, Professor Dame Carol Robinson, Shows Power of ... | globenewsw... |
| 07.03.2022 | OMass Establishes Scientific Advisory Board of Leading Exper... | PRESS RELEASE OMass Establishes Scientific Advisory Board of Leading Experts in the Use of Biophysic... | globenewsw... |
| 28.02.2022 | OMass’s OdyssION™ Drug Discovery Platform Makes Progress in ... | PRESS RELEASE OMass’s OdyssION™ Drug Discovery Platform Makes Progress in Drugging the Undruggable, ... | globenewsw... |
| 21.02.2022 | OMass Therapeutics to Present at Upcoming Conferences | PRESS RELEASE OMass Therapeutics to Present at Upcoming Conferences Oxford, United Kingdom – 21 Febr... | globenewsw... |
| 04.11.2021 | OMass Unveils Rich Drug Discovery Pipeline Targeting Intract... | PRESS RELEASE OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugg... | globenewsw... |
| 18.02.2020 | Drug discovery in HD: Oxford spinoff's mass spectrome... | The technology used to detect explosives at airports — mass spectrometry — is being pilo... | endpts.com... |
Show more